Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers (Q38974499)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

0 references

oncolytic virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

T Du

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

G Shi

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Y M Li

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

J F Zhang

4

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

H W Tian

5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Y Q Wei

6

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

H Deng

7

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

D C Yu

8

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

18 July 2014

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Cancer Gene Therapy

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

340-348

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Structure of murine CTLA-4 and its role in modulating T cell responsiveness

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

T-cell regulation by CD28 and CTLA-4.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Functions of granulocyte-macrophage colony-stimulating factor.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Recent progress in the battle between oncolytic viruses and tumours

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Interleukin 1 stimulates fibroblasts to synthesize granulocyte-macrophage and granulocyte colony-stimulating factors. Mechanism for the hematopoietic response to inflammation

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2014.34

21 January 2018

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25034886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/25034886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulation of CTLA-4 expression during T cell activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25034886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25034886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4

1 reference

https://pubmed.ncbi.nlm.nih.gov/25034886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages

1 reference

https://pubmed.ncbi.nlm.nih.gov/25034886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/25034886

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/CGT.2014.34

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38974499&oldid=2202405669"